

45. Hawi A, Alcorn H, Berg J, Hines C, Hait H, Sciascia T. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. *BMC Nephrol*. 2015;16:47.
46. Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol*. 2009;89:45-51.
47. Hashimoto T, Satoh T, Yokozeki H. Prurigo successfully treated with duloxetine hydrochloride. *Australas J Dermatol*. 2019;60:237-239.
48. Griffin JR, Davis MDP. Amitriptyline/ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster. *J Drugs Dermatol*. 2015;14:115-118.
49. Zalaudek I, Petrillo G, Baldassarre MA, et al. Amitriptyline as therapeutic and not symptomatic approach in the treatment of prurigo nodularis: a pilot study. *G Ital Dermatol Venereol*. 2006;141:433-437.
50. Boozalis E, Khanna R, Zampella JG, Kwatra SG. Tricyclic antidepressants for the treatment of chronic pruritus [e-pub ahead of print]. *J Dermatolog Treat*; 2019. <https://doi.org/10.1080/09546634.2019.1623369>. Accessed August 14, 2020.
51. Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor a antibody for atopic dermatitis. *N Engl J Med*. 2017;376:826-835.
52. Schneider LC. Ditching the itch with anti-type 2 cytokine therapies for atopic dermatitis. *N Engl J Med*. 2017;376:878-879.
53. Park B. Nemolizumab gets breakthrough therapy status for prurigo nodularis. Available at: <https://www.empr.com/home/news/nemolizumab-gets-breakthrough-therapy-status-for-prurigo-nodularis/>. Accessed February 23, 2020.
54. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. *N Engl J Med*. 2020;382:706-716.
55. Khanna R, Khanna R, Denny G, Kwatra SG. Cannabinoids for the treatment of chronic refractory pruritus [e-pub ahead of print]. *J Dermatolog Treat*; 2019. <https://doi.org/10.1080/09546634.2019.1639603>. Accessed August 14, 2020.
56. Zhai LL, Savage KT, Qiu CC, Jin A, Valdes-Rodriguez R, Mollanazar NK. Chronic pruritus responding to dupilumab—a case series. *Medicines (Basel)*. 2019;6:72.
57. Mollanazar NK, Elgash M, Weaver L, Valdes-Rodriguez R, Hsu S. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. *JAMA Dermatol*. 2019;155:121-122.
58. Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab treatment for generalized prurigo nodularis. *JAMA Dermatol*. 2019;155:118-120.
59. Napolitano M, Fabbrocini G, Scalvenzi M, Nisticò SP, Dastoli S, Patruno C. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. *Dermatitis*. 2020;31:81-84.
60. Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. *JAAD Case Rep*. 2019;5:471-473.

Answers to CME examination

Identification No. JB1220

December 2020 issue of the Journal of the American Academy of Dermatology.

Williams KA, Huang AH, Belzberg M, Kwatra SG. *J Am Acad Dermatol* 2020;83:1567-75.

1. b
2. a

3. c
4. b